Avivagen Inc.
Avivagen Inc.
Your view on VIVXF
Overview
What the company does, where it operates, and who runs it.
About Avivagen Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- G. F. Kym Anthony
- Headquarters
- 100 Sussex Drive, Ottawa, ON, CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- G. F. Kym Anthony
- Headquarters
- 100 Sussex Drive, Ottawa, ON, CA
Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity.
The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system.
It serves in the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Avivagen Inc., and the rating behind it. VIVXF last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Avivagen Inc.. Starting points for Avivagen Inc.: EPS -$0.09, beta 0.45 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Avivagen Inc.. Avivagen Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Avivagen Inc.. Trailing twelve-month EPS for Avivagen Inc. stands at -$0.09. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Avivagen Inc.. Avivagen Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Avivagen Inc. valued side by side against its closest peers. Avivagen Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Avivagen Inc., and how their positions are changing. At a $7,769 market value, institutional positions materially move Avivagen Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Avivagen Inc. executives and directors. Shares of Avivagen Inc. have traded between $0.0001 and $0.0012 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Avivagen Inc.. Avivagen Inc. is a $7,769 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Avivagen Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Avivagen Inc.. Coverage tracks Avivagen Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.